Vanda Pharmaceuticals (FRA:VM4) EV-to-Revenue : -0.34 (As of May. 17, 2024)

View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vanda Pharmaceuticals's enterprise value is €-55.5 Mil. Vanda Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €164.1 Mil. Therefore, Vanda Pharmaceuticals's EV-to-Revenue for today is -0.34.

The historical rank and industry rank for Vanda Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

FRA:VM4' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.34 Med: 2.8 Max: 14.55
Current: -0.34

During the past 13 years, the highest EV-to-Revenue of Vanda Pharmaceuticals was 14.55. The lowest was -1.34. And the median was 2.80.

FRA:VM4's EV-to-Revenue is ranked better than
93.86% of 1043 companies
in the Biotechnology industry
Industry Median: 8.03 vs FRA:VM4: -0.34

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-17), Vanda Pharmaceuticals's stock price is €4.86. Vanda Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €2.85. Therefore, Vanda Pharmaceuticals's PS Ratio for today is 1.71.

Vanda Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Vanda Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals EV-to-Revenue Chart

Vanda Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

2.56

1.48

1.70

-0.14

-0.71

Vanda Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															-0.39	-0.42	-1.09	-0.71	-0.82

Competitive Comparison of Vanda Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Vanda Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vanda Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's EV-to-Revenue falls into.

Vanda Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Vanda Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	-55.534	/	164.059
	=	-0.34

Vanda Pharmaceuticals's current Enterprise Value is €-55.5 Mil.
Vanda Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €164.1 Mil.

Vanda Pharmaceuticals (FRA:VM4) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Vanda Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	4.86	/	2.846
	=	1.71

Vanda Pharmaceuticals's share price for today is €4.86.
Vanda Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.85.

Vanda Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanda Pharmaceuticals (FRA:VM4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (FRA:VM4) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

VNDA:USA VM4:Germany

Address

2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037

Website

https://www.vandapharma.com

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.

Vanda Pharmaceuticals (FRA:VM4) Headlines

No Headlines